UBS Upgrades Quest Diagnostics (DGX) to Buy

November 14, 2016 7:07 AM EST
Get Alerts DGX Hot Sheet
Price: $91.07 +0.08%

Rating Summary:
    10 Buy, 19 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 1 | Down: 2 | New: 3
Trade DGX Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

UBS upgraded Quest Diagnostics (NYSE: DGX) from Neutral to Buy with a price target of $90.

Analyst A.J. Rice said, "At its investor day on November 11, Quest management laid out the growth outlook for the company's next 3-5 years. From 2017 to 2020, DGX expects to post annual revenue growth of 3-5%, with 1-2% coming from acquisitions. Earnings growth over the same period is expected to be in the mid-to-single digit percentage growth range. Finally, free cash flow is projected to grow in the high single digit growth range. These growth targets represent reiterations and in some cases increases in company targets. In addition, DGX management says it approached the outlook in a way that leaves the potential it can be at the high end of expectations."

For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.

Shares of Quest Diagnostics closed at $81.46 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Upgrades

Related Entities

UBS, Earnings

Add Your Comment